At least 11 companies in the industry launched initial public offerings, while only two did so in 2013.
Eye surgeons have faced a growing problem of drug resistance, even as use of IVT injections has been increasing rapidly.
Federal officials have made legislative and regulatory efforts to incentivize the development of these drugs.
Omidria's reimbursement will be based on the product's wholesale acquisition cost of $400 to $500 per single-use vial.
While this battle is outside the confines of ophthalmology, it may have far-reaching implications.
Ophthalmic companies gearing up in this segment include Pfenex, whose lead program involves a Lucentis biosimilar in Phase I/II clinical study.
The Massachusetts facility compounded injectable Avastin and triamcinolone acetonide for ophthalmic use.
J. Michael Pearson refers to the whole saga as a speedbump and says has no plans to work on another deal with William Ackman.
You are not currently logged in.
©2017 Market Scope
Lost your Password